Nipocalimab (M281) led to a rapid and sustained response at all four dosing regimens, while causing significant reductions in disease severity among people with generalized myasthenia gravis (gMG), top-line results of the Phase 2Â Vivacity-MG clinical trial show. The investigational therapy, developed by Momenta Pharmaceuticals, also showed a…
A new type of immunotherapy successfully eliminated immune B-cells that wrongly target the MuSK protein in people with MuSK-associated myasthenia gravis (MG), a study in mice found. While the treatment effectively killed damaging B-cells, it spared healthy cells, setting the stage for its possible testing in people. …
The type of antibodies found in children with myasthenia gravis (MG) was the primary predictor of disease remission, or not requiring medication for one full year, a study showed. Additional factors influencing remission were being younger than 10 years old at…
Get regular updates to your inbox.